CHU Clermont-Ferrand, pôle BMAP, F-63003 Clermont-Ferrand, France.
CHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France; Université Clermont Auvergne, CNRS 6023-LMGE, EPIE, F-63001 Clermont-Ferrand, France.
Clin Microbiol Infect. 2022 Nov;28(11):1503.e5-1503.e8. doi: 10.1016/j.cmi.2022.06.030. Epub 2022 Jul 2.
To describe Delta/Omicron SARS-CoV-2 variants co-infection detection and confirmation during the fifth wave of COVID-19 pandemics in France in 7 immunocompetent and epidemiologically unrelated patients.
Since December 2021, the surveillance of Delta/Omicron SARS-CoV-2 variants of concern (VOC) circulation was performed through prospective screening of positive-samples using single nucleotide polymorphism (SNP) PCR assays targeting SARS-CoV-2 S-gene mutations K417N (Omicron specific) and L452R (Delta specific). Samples showing unexpected mutational profiles were further submitted to whole genome sequencing (WGS) using three different primer sets.
Between weeks 49-2021 and 02-2022, SARS-CoV-2 genome was detected in 3831 respiratory samples, of which 3237 (84.5%) were screened for VOC specific SNPs. Unexpected mutation profiles suggesting a dual Delta/Omicron population were observed in 7 nasopharyngeal samples (0.2%). These co-infections were confirmed by WGS. For 2 patients, the sequence analyses of longitudinal samples collected 7 to 11 days apart showed that Delta or Omicron can outcompete the other variant during dual infection. Additionally, for one of these samples, a recombination event between Delta and Omicron was detected.
This work demonstrates that SARS-CoV-2 Delta/Omicron co-infections are not rare in high virus co-circulation periods. Moreover, co-infections can further lead to genetic recombination which may generate new chimeric variants with unpredictable epidemic or pathogenic properties that could represent a serious health threat.
描述 7 例免疫功能正常且流行病学无关的患者在法国第五波 COVID-19 大流行期间 Delta/Omicron SARS-CoV-2 变体合并感染的检测和确认情况。
自 2021 年 12 月以来,通过针对 SARS-CoV-2 S 基因突变 K417N(Omicron 特异性)和 L452R(Delta 特异性)的单核苷酸多态性(SNP)PCR 检测对阳性样本进行前瞻性筛查,监测 Delta/Omicron SARS-CoV-2 关注变体(VOC)的传播情况。对显示意外突变谱的样本,使用三种不同的引物组进行全基因组测序(WGS)。
在 2021 年第 49 周至 2022 年第 02 周期间,从 3831 个呼吸道样本中检测到 SARS-CoV-2 基因组,其中 3237 个(84.5%)样本用于筛选 VOC 特异性 SNPs。在 7 个鼻咽样本(0.2%)中观察到提示双 Delta/Omicron 人群的意外突变谱。这些合并感染通过 WGS 得到确认。对于 2 名患者,对相隔 7 至 11 天收集的纵向样本进行序列分析表明,在双感染期间,Delta 或 Omicron 可竞争过另一种变体。此外,在其中一个样本中,检测到 Delta 和 Omicron 之间的重组事件。
这项工作表明,在高病毒共流行期间,SARS-CoV-2 Delta/Omicron 合并感染并不罕见。此外,合并感染可能进一步导致遗传重组,这可能产生具有不可预测的流行或致病特性的新嵌合变体,这可能构成严重的健康威胁。